lunes, 20 de febrero de 2012

Aceite de pescado y propóleo para evitar efectos secundarios del valproato (antiepiléptico)

Fish liver oil and propolis as protective natural
products against the effect of the anti-epileptic
drug valproate on immunological markers
of bone formation in rats
Amany S.E. Elwakkad, Karima A.I. El. ElShamy, H. Sibaii

Summary
Epilepsy is a major public health problem affecting nearly 50 million people world
wide. Treatment with anti-epileptic drugs (AEDs) is generally chronic if not life long and may
be associated with significant metabolic effects including decreased bone mass and increased
fractures. The aim of this work was to investigate the protective role of fish liver oil and propolis
against the effect of the drug valproate that is widely used for treatment of epilepsy. Group of
40 rats was divided into four groups each contain 10 rats. The first group (group I) is healthy
normal rats, as control. Epilepsy was conducted in the rest of the rats. The epileptic rats were
divided into three subgroups: group II was epileptic group, supplemented orally with valproate.
The third group was epileptic group which supplemented orally with valproate in concomitant
with fish liver oil, the last group; group IV was epileptic group which supplemented orally with
valproate in concomitant with propolis. In the present study oral administration of valproate
to the epileptic rats by a dose of 400 mg/kg/daily for six months (group II) resulted in a significant
increase of bone alkaline phosphatase, osteocalcin and
N-telepeptide of type 1 collagen
(NTX) relative to the control group. There were increase of receptor activator of NF kappa B
ligand (RANKL), tumor necrosis factor — alpha (TNF-) and decrease of osteoprotegrin (OPG)
compared to normal control. Administration of fish liver oil orally in a dose of 0.4 mg/kg daily
in concomitant with valproate 400 mg/kg daily for six months (group III), result in reduction of

-telepeptide of type 1 collagen (NTX) in comparison to group II and with no significant increase
than the control (group I). There were high significant increase of bone alkaline phosphatase
and osteocalcin compared to control group I. There was high significant increase of bone alkaline
phosphatase than group II and increase in osteocalcin, and decrease in
N-telepeptide of
type 1 collagen (NTX) compared to group II. A significant increase in osteoprotegrin (OPG) in
comparison to group II and to control (group I) with a decrease in RANKL compared to group II
and with no significant increase than normal control (group I). The TNF-
showed a significant
decrease compared to group II with no significant increase than normal control. Administration

of propolis orally in a dose of 50 mg/kg daily in combination with valproate 400 mg/kg/daily for

six months (group IV) cause increase in bone alkaline phosphatase with no statistical difference

between osteocalcin and
N-telepeptide of type 1 collagen (NTX) and normal control (group I).

There were increase in bone alkaline phosphatase than group II but less than group III. The

increase in osteocalcin in-group III (fish oil group) was significantly higher than in-group IV and

there was no statistical difference between it and group II. Where the
N-telepeptide of type 1

collagen (NTX) the bone resorption marker was significantly higher than Group III and significantly

lower than group II. There was a decrease of RANKL in comparison to group II with no significant

difference than group III and a significant increase than control group. There was an increase in

osteoprotegrin (OPG) in comparison to control (group I), group II and from group III. There was

decrease in TNF-
than group III, group I and group II.

In conclusion, in epileptic rats treated with valproate (which cause osteoporosis) fish liver oil

and propolis increase the bone formation markers and decrease the bone resorption one’s. They

increase the OPG and decrease TNF-, and RANKL which inhibit the osteoclastogenesis. We recommend

the use of Fish Oil, or propolis as a prophylactic treatment for epileptic patients using

valproate against the side effect of valproate on bone.

¨Ï 2008 Elsevier

No hay comentarios:

Publicar un comentario